Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hovione to buy Pfizer's Irish API facility

This article was originally published in Scrip

Executive Summary

The Portuguese active pharmaceutical ingredient manufacturer Hovioneis to buyPfizer's Loughbeg API site in County Cork, Ireland, for an undisclosed sum. The deal should be completed by April 2009. Over the next two years Hovione Cork will validate processes for new compounds up for approval and will transfer products from its Loures site in Portugal. Between 70 and 80 employees will work at the plant, which will increase the company's manufacturing capacity by 427m3, up from 810m3. The new plant is equipped for low temperature chemistry and hydrogenation and also gives the company the capacity for producing spray-dried formulations. County Cork has the highest concentration of API production in the world, a good talent pool and a strong reputation for good manufacturing practices with health authorities, says the company. Hovione will continue to provide Pfizer with manufacturing services. IDA Ireland, the Industrial Development Agency, has welcomed the deal.

You may also be interested in...



England’s NICE Recommends BMS/Celgene’s Revlimid For Follicular Lymphoma

Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.

Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

Brazilian Regulator Approves New Advanced Therapy Regulations

Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007597

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel